Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study

Padrik, Peeter; Valter, Ann; Valter, Epp; Baburin, Aleksei; Innos, Kaire

doi:10.1080/0284186x.2016.1243804

Cited by 24 publications

(29 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with LM are mostly elderly and have been shown to have a relative survival rate of 104% compared with the general population, while patients with LMM have a relative survival rate of 99% after treatment (1). In contrast, studies on malignant melanoma (non-LMM) showed a relative 5-year survival of 76-83.4% after treatment (20,21). The current study found no LM-or LMM-related deaths.…”

Section: Discussioncontrasting

confidence: 54%

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment

Tio¹,

Montfrans²,

Ruijter³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

SIGNIFICANCE Lentigo maligna is treated to prevent progression to lentigo maligna melanoma. The current treatment of choice for lentigo maligna is surgical excision. Topical imiquimod is an alternative option. In this study, topical imiquimod treatment was successful in 84.2% of patients with lentigo maligna. Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM). Surgery is the gold standard, but an alternative treatment is offlabel topical imiquimod. The aim of this study was to evaluate the effectiveness of 5% topical imiquimod treat ment for lentigo maligna. In the period 2007-2017 57 patients with lentigo maligna were treated with off-label topical imiquimod once daily for 12 weeks. Complete clinical clearance was observed in 48 patients (84.2%) and partial clearance in 3 patients (5.3%). Three patients (5.3%) showed no response and another 3 patients (5.3%) stopped treatment due to side-effects. After 4.5 years, during follow-up, one patient developed a lentigo maligna melanoma, which was subsequently excised. Treatment with topical imiquimod resulted in complete clearance of lentigo maligna in 48 out of 57 patients (84.2%). Topical imiquimod is an acceptable treatment option for patients with lentigo maligna who prefer topical treatment to surgery or radiotherapy.

show abstract

Section: Discussioncontrasting

confidence: 54%

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment

Tio¹,

Montfrans²,

Ruijter³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…In Serbia between 2005 and 2010 the median Breslow thickness reported was 3 mm [38]. In Estonia the proportion of thin melanoma (T1 of TNM classification) increased from 7% in men and 14% in women in 1992 to 34% in men and 41% in women in 2010-2012, while the proportion of T4 tumors decreased slightly [39]. In Croatia the mean Breslow thickness reported in 2012 was 2 mm, with 75% of T4 tumors found in men and 60% of T1 tumors in women [40].…”

Section: Melanoma Survival In Europementioning

confidence: 98%

Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities

Forsea

2020

Dermatol Pract Concept

View full text Add to dashboard Cite

Melanoma claims annually more than 20,000 lives in Europe and is an important public health burden through its continuously increasing incidence and with its high mortality, costs, and complexity of care in advanced stages. Epidemiological surveillance is indispensable for the research into its causes, new prognostic markers, and innovative therapies, as well as for the building of efficient cancer control plans. However, important differences in the sources and availability of accurate epidemiological data exist among European countries and regions, contributing to a heterogeneous picture with 20-fold differences in the reported national melanoma incidence rates, divergent mortality trends, and solid disparities in survival across the Continent. Countries in the eastern half of Europe report the lowest incidence rates, but high case fatality, persisting and increasing mortality, a higher proportion of thicker tumors and late diagnosis, and lower survival rates. They are the least well equipped with quality cancer registration and reporting, and they lag behind in efficient cancer control plans implementation. This review highlights the main differences in melanoma epidemiology across Europe, together with an insight into their underlying causes in the areas of melanoma registration, early diagnosis, and prevention. These differences should be acknowledged and understood by physicians, researchers, and all stakeholders involved in improving melanoma care and outcomes, as no one-size-fits-all solution can tackle the melanoma problem in Europe. Instead, there is a need for nuanced strategies, adapted to the heterogeneous national and regional contexts, that would build on European diversity to eliminate the outcome disparities.

show abstract

“…Melanoma is one of the most notoriously invasive neoplasia, and it originates from cells that produce melanin [1]. The prognosis of melanoma remains dismal because melanoma is refractory to the current therapies [2,3]. Moreover, the exact cause of malignant melanoma is very complex and poorly understood.…”

Section: Introductionmentioning

confidence: 99%

Circ-FOXM1 contributes to cell proliferation, invasion, and glycolysis and represses apoptosis in melanoma by regulating miR-143-3p/FLOT2 axis

et al. 2020

View full text Add to dashboard Cite

Background: Numerous literatures have demonstrated that circular RNAs (circRNAs) are involved in multiple types of tumors. However, the effects of circRNAs in melanoma are not very clear. In this study, we aimed to investigate the roles and mechanisms of circ-FOXM1 in melanoma. Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to determine the expression of circ-FOXM1, microRNA-143-3p (miR-143-3p), and Flotillin 2 (FLOT2) mRNA. 3-(4,5-Dimethyl-2-thiazolyl)-2,5diphenyl-2-H-tetrazolium bromide (MTT) assay, flow cytometry analysis, and transwell assay were employed to test cell proliferation, apoptosis, and invasion, respectively. The glucose consumption and lactate production were examined by specific kits. Western blot assay was utilized for the detection of hexokinase2 (HK2), pyruvate kinase isozyme type M2 (PKM2), and FLOT2. Dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay were employed to verify the targeting association between miR-143-3p and circ-FOXM1 or FLOT2. A murine xenograft model was established to explore the effect of circ-FOXM1 in vivo. Results: Circ-FOXM1 was elevated and miR-143-3p was reduced in melanoma tissues and cells. Circ-FOXM1 deficiency impeded cell proliferation, invasion, and glycolysis and facilitated cell apoptosis in melanoma in vitro and tumorigenesis in vivo. Circ-FOXM1 acted as a sponge of miR-143-3p and the impacts of circ-FOXM1 silencing on cell proliferation, apoptosis, invasion, and glycolysis were overturned by miR-143-3p deletion. Moreover, FLOT2 was a target gene of miR-143-3p and FLOT2 overexpression rescued the inhibitory effect of miR-143-3p on melanoma progression. Conclusion: Circ-FOXM1 facilitated the development of melanoma by upregulating FLOT2 through miR-143-3p.

show abstract

Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study

Cited by 24 publications

References 24 publications

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment

Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities

Circ-FOXM1 contributes to cell proliferation, invasion, and glycolysis and represses apoptosis in melanoma by regulating miR-143-3p/FLOT2 axis

Contact Info

Product

Resources

About